443B751F-4F0B-45A1-BC83-24E446E8E573
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 19.97371879106439
- age_years
- 48
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.452
- OXIDATIVE_PHOSPHORYLATION+0.423
- DNA_REPAIR+0.286
- TGF_BETA_SIGNALING+0.286
- PROTEIN_SECRETION+0.281
- ADIPOGENESIS+0.270
- INTERFERON_ALPHA_RESPONSE+0.262
- APOPTOSIS+0.223
- INTERFERON_GAMMA_RESPONSE+0.216
- UV_RESPONSE_UP+0.216
Top 10 suppressed
- KRAS_SIGNALING_DN-0.184
- PANCREAS_BETA_CELLS-0.181
- SPERMATOGENESIS-0.181
- CHOLESTEROL_HOMEOSTASIS-0.154
- INFLAMMATORY_RESPONSE-0.096
- ESTROGEN_RESPONSE_LATE-0.084
- MYOGENESIS-0.080
- G2M_CHECKPOINT-0.050
- MYC_TARGETS_V2-0.047
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C969CDC5-D2DC-4F7B-B84B-C53CEF26B2CF | — | — | 0.808 |
| 2 | B7B0DDFA-C204-4F84-A1C5-8F836668B99F | — | — | 0.797 |
| 3 | E9D4A83F-EADA-4330-911A-8F02393E0BA3 | — | — | 0.792 |
| 4 | SRR934985 | — | — | 0.782 |
| 5 | 95286AA4-B357-41FE-8051-3BD3EBE93885 | — | — | 0.776 |
| 6 | 022275BA-F672-49C5-887B-CCF24A20848F | — | — | 0.772 |
| 7 | 1A796849-8FD9-4B27-9CD9-A17B04CBE264 | — | — | 0.768 |
| 8 | 7999ABCD-7441-4437-AE78-7BF5F7FBBE36 | — | — | 0.762 |
| 9 | 37586AAC-159B-41F9-9078-C2F7888753AC | — | — | 0.762 |
| 10 | C642D475-8BD8-44CA-B07E-A6822B2224C4 | — | — | 0.758 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.452 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.423 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.286 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.286 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.281 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.262 | Inavolisib | — uncovered |
| APOPTOSIS | 0.223 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.216 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.216 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.214 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.212 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.205 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.204 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.179 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.144 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.137 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.132 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.113 | Idelalisib | — uncovered |